Clinical Trials Logo

Obstructive Sleep Apnea clinical trials

View clinical trials related to Obstructive Sleep Apnea.

Filter by:

NCT ID: NCT03647462 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients

COPD Readmit
Start date: September 23, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether early diagnosis of OSA and initiation of and adherence to CPAP therapy in patients hospitalized for chronic obstructive pulmonary disease reduce 30-day hospital readmission rates.

NCT ID: NCT03646552 Recruiting - Clinical trials for Obstructive Sleep Apnea

A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea

Start date: June 4, 2018
Phase: Phase 2
Study type: Interventional

This is a sponsored proof of concept study with the purpose to examine the safety, tolerability and feasibility of THX-110 (Dronabinol (synthetic Δ9-THC) and PEA) for the treatment of adults with Obstructive Sleep Apnea.

NCT ID: NCT03640793 Recruiting - Clinical trials for Obstructive Sleep Apnea

Prospective Evaluation of a Palato-Pharyngeal Implant System (PPIS) Obstructive Sleep Apnea Syndrome (OSAS)

Start date: October 9, 2017
Phase: N/A
Study type: Interventional

Prospective Evaluation of a Palato-Pharyngeal Implant System (PPIS) for the Treatment of Snoring and Obstructive Sleep Apnea Syndrome (OSAS): A Pilot Study.

NCT ID: NCT03640052 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Pharmacological Activation of HMN for OSA

OSA12
Start date: September 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201L, LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA severity during sleep.

NCT ID: NCT03632382 Recruiting - Clinical trials for Obstructive Sleep Apnea

Non-invasive Device for the Screening and Diagnosis of Sleep Apnea Syndrome

Episas
Start date: July 27, 2018
Phase: N/A
Study type: Interventional

This prospective study aims to establish and evaluate a predictive model to diagnose OSA with maxillofacial characteristics 3D acquisition.

NCT ID: NCT03627169 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

PSG Validation of MATRx Plus AHI

Start date: August 17, 2017
Phase:
Study type: Observational

Obstructive sleep apnea (OSA) is a common disease that carries significant risks for cardiovascular disease, mortality, and economic costs. Almost thirty years ago, initial population studies found the prevalence of OSA to be five to nine percent of the adult population. Excess body weight is a risk factor for the development of OSA, and the recent rise in prevalence of obesity has led to revised estimates of OSA prevalence, now at seventeen per cent of the adult population. OSA is poorly recognized clinically; 85% of apneics remain undiagnosed and untreated. Currently, the diagnosis of OSA commonly relies on an overnight, in-hospital polysomnogram (PSG). Due to the extensive attachments to the body surface required in a PSG, it has developed a negative impression. Any effective solution to the public health challenges posed by sleep apnea will have to consider the need for less cumbersome and off-putting methods. Zephyr Sleep Technologies has developed a device that has been approved for use in Canada. The MATRx plus device functions as both a Level III sleep recorder (records respiratory airflow, respiratory effort, pulse rate, and arterial oxygen saturation) as well as a home-based system to select patients for oral appliance therapy. The American Academy of Sleep Medicine (AASM) recommends the use of apnea-hypopnea index (AHI) for the diagnosis and categorization of OSA severity. The Level III function of the MATRx plus device is approved for use in Canada with two autoscoring methods: oxygen desaturation index, ODI and apnea-hypopnea index, AHI, but requires further validation of AHI for clearance by the US Food and Drug Administration (FDA). The proposed research will validate the AHI autoscoring function of the MATRs plus Level III home sleep recorder by comparing it to data recorded in a PSG, which is considered to be the gold standard for sleep testing. Though the effectiveness of the AHI autoscoring algorithm has been previously established, it has not been validated against PSG data. Additionally, other parameters such as snoring will be examined in order to develop scoring algorithms for other facets of sleep disordered breathing.

NCT ID: NCT03616327 Recruiting - Clinical trials for Obstructive Sleep Apnea

Workflow Validation of an In-Home Feedback Controlled Mandibular Positioner

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to test the workflow of the MATRx and MATRx plus feedback controlled mandibular positioner in its intended setting and considerations related to decision making by the care provider. The workflow includes the participant's recruitment into the study, the screening process, visits at the dentist, home sleep tests, and the decision made regarding oral appliance therapy based on the results of the sleep tests.

NCT ID: NCT03613558 Withdrawn - Clinical trials for Obstructive Sleep Apnea

Dex as Analgesic Adjuvant in OSA Patients

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess whether intravenous peri-operative Dexmedetomidine reduces opioid requirements and or improves pain control after Uvulopalatopharyngoplasty (UPPP) in patients with obstructive sleep apnea (OSA).

NCT ID: NCT03605485 Completed - Clinical trials for Obstructive Sleep Apnea

The Evaluation of a Novel Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea

Start date: August 7, 2018
Phase: N/A
Study type: Interventional

This investigation is a prospective, non randomized, non blinded study. This investigation is designed to evaluate the performance, comfort and ease of use with the F&P trial nasal pillows mask amongst Obstructive Sleep Apnea (OSA) participants.

NCT ID: NCT03600246 Recruiting - Clinical trials for Obstructive Sleep Apnea

Prospective Observational Registry for Obstructive Sleep Apnea in Patients With Acute Myocardial Infarction

OSAAMI
Start date: June 1, 2018
Phase:
Study type: Observational

Obstructive sleep apnea (OSA) has been known as a risk factor for coronary artery disease, heart failure, cerebrovascular accident and atrial fibrillation. One study reported that patients with OSA have more atherosclerotic plaque burden in intravascular ultrasonography examination. Among patients who admitted with acute myocardial infarction (AMI), 65.7% (69 of 105) patients were diagnosed with OSA. Other long-term follow-up study revealed that 45.4% of patients (594 of 1311) who performed percutaneous coronary intervention (PCI) were diagnosed with OSA. Moreover, the OSA group was a significant independent predictor of major adverse cardiac and cerebrovascular events (MACCEs). Polysomnography (PSG) is the gold standard for the diagnosis of OSA. But, PSG is expensive, time-consuming and difficult to perform immediately. Recently, a portable device named WATCH-PAT (Itamar Ltd, Israel) was developed for the diagnosis of OSA. Validation study demonstrated a high correlation between WATCH-PAT and PSG in apnea-hypopnea index, lowest oxygen saturation and sleep time. This result suggested WATCH-PAT can be performed as an alternative or supportive device of PSG. WATCH-PAT. The portable device also can be useful to detect OSA in bus drivers who can be the reason for public traffic accidents. Moreover, WATCH-PAT can be applied to assess postoperative improvement of OSA. Although OSA is known as one of the risk factors for cardiovascular disease, there is a lack of evidence to recommend of the evaluation of sleep disorder in patient with coronary artery disease. Awareness and compliance for OSA are very low in both patients and cardiologists. Active diagnosis and treatment are definitely needed. Therefore, the primary endpoint of this study is to evaluate the prevalence of OSA in AMI patients who treated PCI. The secondary endpoint is to evaluate the 1-year incidence rate of MACCEs according to the presence or absence of OSA.